Thoracic Endovascular Repair Versus Open Surgery for Blunt Injury

Overview

This study aims to increase understanding of the short-term and long-term outcome of blunt aortic injury (BAI) and to discern if there is an advantage resulting from the type of operative treatment used to manage it, either the classic open surgical repair or a newer technique known as thoracic endovascular repair (TEVAR). Specifically, this study will answer the following questions regarding patients suffering BAI: 1. What clinical variables affect short-term mortality and neurologic outcome? 2. What are the long-term treatment-associated complications of open repair and TEVAR? 3. In patients with a similar injury and physiologic profile, is there a survival advantage resulting from the type of operative treatment?

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: December 2016

Detailed Description

Blunt aortic injury (BAI) is responsible for 16% of traffic fatalities. Historically, about 80% of these deaths occur at the scene and 20% are transported to the hospital. With the development of systems of trauma care and other advances, it is likely that more patients with BAI will arrive alive at trauma centers. Patients with BAI who arrive at the hospital can be treated with either classic open surgery or with endovascular techniques. A relatively new endovascular technique, thoracic endovascular repair (TEVAR), has been recommended by the Society of Vascular Surgery (SVS) as the procedure of choice for BAI. However, the data on which this was based was described as "very low quality evidence" (Grade 2, C), i.e., no better than expert opinion. It is important to note that the committee responsible for the recommendation of the SVS consisted of vascular surgeons, without input from trauma surgeons who are primarily responsible for the management of the trauma patient with BAI. This omission may have biased the literature review in favor of TEVAR because there was inadequate data in the published research to account for disparities of injury severity and physiologic compromise, both of which significantly impact outcome. The investigators reviewed the recent literature on the management of BAI to determine if sufficient data exists to perform an "apples to apples" comparison between TEVAR and classic open surgery. The investigators believe that sufficient clinical equipoise has not been reached such that a prospective, randomized clinical trial could be undertaken. Therefore, the investigators aim to conduct a multicenter 5-year combined historical cohort and concurrent cohort observational study of the short-term and long-term outcome of BAI. Such a study would answer the following clinically relevant questions in patients suffering BAI: 1. What clinical variables affect short-term mortality and neurologic outcome? 2. What are the long-term treatment-associated complications of open repair and TEVAR? 3. In patients with a similar injury and physiologic profile, is there a survival advantage resulting from the type of operative treatment? The proposed study will be done by Scripps Mercy Hospital Trauma Service with the participation of interested member trauma centers of the Multicenter Trials Group of the Western Trauma Association.

Interventions

  • Procedure: Open repair of thoracic aorta injury
    • open surgical management of aortic injury
  • Procedure: TEVAR
    • Use of endovascular (minimally invasive) techniques for repair of aortic injury

Arms, Groups and Cohorts

  • Blunt Aortic Injury Patients
    • Trauma patients with blunt aortic injury. This Cohort of trauma patients will require management with one of two interventions. They will require either; Open repair of thoracic aorta injury (Intervention #1) or TEVAR (Intervention #2). As of yet the short term and long term outcomes of these two treatments have not been directly compared.

Clinical Trial Outcome Measures

Primary Measures

  • Short-Term Mortality
    • Time Frame: During the index hospitalization, an expected average of 30 days from time of injury
    • Cause of death during the index hospitalization (prior to discharge, averaging less than 30 days from the time of injury) will be assessed, as measured by death certificate and autopsy or, if no autopsy, morbidity and mortality review findings. Care withdrawn at request of family will also be noted. Final adjudication of mortality (preventable, non-preventable, or possibly preventable)will be gathered.

Secondary Measures

  • Short-Term Treatment-Associated Complications
    • Time Frame: During the index hospitalization, an expected average of 30 days from time of injury
    • Complications during the index hospitalization (prior to discharge, averaging less than 30 days from time of injury) related specifically to TEVAR or to open repair will be gathered. TEVAR-specific complications to include: endoleak; endocollapse; migration; loss of apposition at proximal landing zone; access complications. Open repair-specific complications to include: VATS for retained hemothorax; empyema.
  • Long-Term Treatment-Associated Complications
    • Time Frame: Up to 5 years following discharge
    • Complications during the 5-year follow-up period post-discharge, related specifically to TEVAR or to open repair will also be gathered. TEVAR-specific complications to include: endoleak; endocollapse; migration; loss of apposition at proximal landing zone; graft infection; wound infection. Open repair-specific complications to include: graft infection; pseudoaneurysm; wound infection.

Participating in This Clinical Trial

Inclusion Criteria

  • Clinical diagnosis of blunt aortic injury (BAI) Exclusion Criteria:

  • Clinical diagnosis of penetrating aortic injury

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Scripps Health
  • Collaborator
    • Western Trauma Association
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • Steven R Shackford, MD, Principal Investigator, Scripps Mercy Hospital, Division of Trauma Surgery

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.